Mechanistic understanding and significance of small peptides interaction with MHC class II molecules for therapeutic applications

Immunological Reviews

Volumn 272, Issue 1, 2016, Pages 151-168

  Afridi, Saifullah ^a   Hoessli, Daniel C ^a   Hameed, Muhammad Waqar ^a  

^a UNIVERSITY OF KARACHI   (Pakistan)

Author keywords

antigen presentation; MHC class II molecules; MHC loading enhancers; small peptides

Indexed keywords

DIPEPTIDE; HLA DM ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE;

ALLELE; ALLOSTERISM; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; CD4+ T LYMPHOCYTE; CELL SURFACE; CONFORMATIONAL TRANSITION; ENHANCER REGION; FLUORESCENCE POLARIZATION; GENETIC ORGANIZATION; GOLGI COMPLEX; HUMAN; HYDROGEN BOND; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; TRANS GOLGI NETWORK;

EID: 84975527586     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12435     Document Type: Review

References (185)

1. Dai S, et al. Crossreactive T cells spotlight the germline rules for αβ T cell-receptor interactions with MHC molecules. Immunity 2008;28:324–334.
2. Huseby ES, et al. How the T cell repertoire becomes peptide and MHC specific. Cell 2005;122:247–260.
3. + T cells elicit host immune responses to MHC class II – ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells. J Immunol 2010;184:5654–5662.
4. + T cells in immunity to viruses. Nat Rev Immunol 2012;12:136–148.
5. Critchfield JM, et al. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science 1994;263:1139–1143.
6. Kim E, Cho K-O, Rothschild A, Sheng M. Heteromultimerization and NMDA receptor-clustering activity of Chapsyn-110, a member of the PSD-95 family of proteins. Neuron 1996;17:103–113.
7. Borgulya P, Kishi H, Muller U, Kirberg J, Vonboehmer H. Development of the CD4 and CD8 lineage of T-cells – instruction versus selection. EMBO J 1991;10:913–918.
8. Liu ZJ, et al. B7 interactions with CD28 and CTLA-4 control tolerance or induction of mucosal inflammation in chronic experimental colitis. J Immunol 2001;167:1830–1838.
9. Dustin ML, Ferguson LM, Chan PY, Springer TA, Golan DE. Visualization of CD2 interaction with LFA-3 and determination of the two-dimensional dissociation constant for adhesion receptors in a contact area. J Cell Biol 1996;132:465–474.
10. Kimura T, Sakamoto H, Appella E, Siraganian RP. Conformational changes induced in the protein tyrosine kinase p72(syk) by tyrosine phosphorylation or by binding of phosphorylated immunoreceptor tyrosine-based activation motif peptides. Mol Cell Biol 1996;16:1471–1478.
11. Kawakami Y, et al. Redundant and opposing functions of two tyrosine kinases, Btk and Lyn, in mast cell activation. J Immunol 2000;165:1210–1219.
12. Gupta S, et al. Anchor side chains of short peptide fragments trigger ligand-exchange of class II MHC molecules. PLoS ONE 2008;3:e1814.
13. Delamarre L, Couture R, Mellman I, Trombetta ES. Enhancing immunogenicity by limiting susceptibility to lysosomal proteolysis. J Exp Med 2006;203:2049–2055.
14. Delamarre L, Mellman OI, Trombetta S. Differential lysosomal proteolysis in antigen presenting cells determines antigen fate and immunogenicity. Cell Struct Funct 2005;30:74.
15. Guagliardi LE, Koppelman B, Blum JS, Marks MS, Cresswell P, Brodsky FM. Co-localization of molecules involved in antigen processing and presentation in an early endocytic compartment. Nature 1990;343:133–139.
16. Harding CV, Unanue ER. Quantitation of antigen-presenting cell MHC class II/peptide complexes necessary for T-cell stimulation. Nature 1990;346:574–576.
17. Bjorkman PJ, Parham P. Structure, function, and diversity of class I major histocompatibility complex molecules. Annu Rev Biochem 1990;59:253–288.
18. Goldrath AW, Bevan MJ. Selecting and maintaining a diverse T-cell repertoire. Nature 1999;402:255–262.
19. Hoepner S, et al. Small organic compounds enhance antigen loading of class II major histocompatibility complex proteins by targeting the polymorphic P1 pocket. J Biol Chem 2006;281:38535–38542.
20. Penn DJ. The scent of genetic compatibility: sexual selection and the major histocompatibility complex. Ethology 2002;108:1–21.
21. Mehra NK, Kaur G. MHC-based vaccination approaches: progress and perspectives. Expert Rev Mol Med 2003;5:1–17.
22. Mehra NK. Histocompatibility antigens. Encyclopedia Life Sci 2001. doi:10.1038/npg.els.0001234.
23. Bolin DR, et al. Peptide and peptide mimetic inhibitors of antigen presentation by HLA-DR class II MHC molecules. Design, structure-activity relationships, and X-ray crystal structures. J Med Chem 2000;43:2135–2148.
24. Jones EY. MHC class I and class II structures. Curr Opin Immunol 1997;9:75–79.
25. Thorsby E. A short history of HLA. Tissue Antigens 2009;74:101–116.
26. Zacharias M, Springer S. Conformational flexibility of the MHC class I alpha(1)-alpha(2) domain in peptide bound and free states: a molecular dynamics simulation study. Biophys J 2004;87:2203–2214.
27. Rammensee HG, Falk K, Rotzschke O. MHC molecules as peptide receptors. Curr Opin Immunol 1993;5:35–44.
28. Yaneva R, Schneeweiss C, Zacharias M, Springer S. Peptide binding to MHC class I and II proteins: new avenues from new methods. Mol Immunol 2010;47:649–657.
29. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. Structure of the human class I histocompatibility antigen, HLA-A2. J Immunol 2005;174:6–12.
30. Brown JH, et al. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993;364:33.
31. Garrett TPJ, Saper MA, Bjorkman PJ, Strominger JL, Wiley DC. Specificity pockets for the side-chains of peptide antigens in HLA-AW68. Nature 1989;342:692–696.
32. Gorga JC, Brown JH, Jardetzky T, Wiley DC, Strominger JL. Crystallization of HLA-DR antigens. Res Immunol 1991;142:401–407.
33. Call MJ. Small molecule modulators of MHC class II antigen presentation: mechanistic insights and implications for therapeutic application. Mol Immunol 2011;48:1735–1743.
34. Jäger E, et al. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer 1997;71:142–147.
35. Maffei A, Papadopoulos K, Harris PE. MHC class I antigen processing pathways. Hum Immunol 1997;54:91–103.
36. Neefjes J, Jongsma ML, Paul P, Bakke O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol 2011;11:823–836.
37. Cresswell P. Intracellular surveillance: controlling the assembly of MHC class I-peptide complexes. Traffic 2000;1:301–305.
38. Wubbolts R, et al. Opposing motor activities of dynein and kinesin determine retention and transport of MHC class II-containing compartments. J Cell Sci 1999;112:785–795.
39. Purcell AW, McCluskey J, Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discovery 2007;6:404–414.
40. Mantegazza AR, Magalhaes JG, Amigorena S, Marks MS. Presentation of phagocytosed antigens by MHC class I and II. Traffic 2013;14:135–152.
41. Cresswell P. Assembly, transport, and function of MHC class-II molecules. Annu Rev Immunol 1994;12:259–293.
42. Marks MS, Blum JS, Cresswell P. Invariant chain trimers are sequestered in the rough endoplasmic-reticulum in the absence of association with HLA class-II antigens. J Cell Biol 1990;111:839–855.
43. Roche PA, Marks MS, Cresswell P. Formation of a nine-subunit complex by HLA class-II glycoproteins and the invariant chain. Nature 1991;354:392–394.
44. Kvist S, Wiman K, Claesson L, Peterson PA, Dobberstein B. Membrane insertion and oligomeric assembly of HLA-DR histocompatibility antigens. Cell 1982;29:61–69.
45. Landsverk OJB, Bakke O, Gregers TF. MHC II and the endocytic pathway: regulation by invariant chain. Scand J Immunol 2009;70:184–193.
46. Layet C, Germain RN. Invariant chain promotes egress of poorly expressed, haplotype-mismatched class II major histocompatibility complex A alpha A beta dimers from the endoplasmic reticulum/cis-Golgi compartment. Proc Natl Acad Sci USA 1991;88:2346–2350.
47. Lotteau V, et al. Intracellular transport of class II MHC molecules directed by invariant chain. Nature 1990;348:600–605.
48. Machamer CE, Cresswell P. Biosynthesis and glycosylation of the invariant chain associated with HLA-DR antigens. J Immunol 1982;129:2564–2569.
49. Sung E, Duncan WR, Streilein JW, Jones PP. Detection of two distinct class II α: β: Ii complexes in the syrian hamster. Immunogenetics 1982;16:425–433.
50. + T-cell selection in mice lacking invariant chain expression. J Exp Med 1993;177:1699–1712.
51. Viville S, et al. Mice lacking the MHC class II-associated invariant chain. Cell 1993;72:635–648.
52. Bryant P, Ploegh H. Class II MHC peptide loading by the professionals. Curr Opin Immunol 2004;16:96–102.
53. Neefjes JJ, Ploegh HL. Inhibition of endosomal proteolytic activity by leupeptin blocks surface expression of MHC class-II molecules and their conversion to SDS resistant alpha-beta-heterodimers in endosomes. EMBO J 1992;11:411–416.
54. Riberdy JM, Avva RR, Geuze HJ, Cresswell P. Transport and intracellular distribution of MHC class II molecules and associated invariant chain in normal and antigen-processing mutant cell lines. J Cell Biol 1994;125:1225–1237.
55. Riberdy JM, Newcomb JR, Surman MJ, Barbosa JA, Cresswell P. HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides. Nature 1992;360:474–477.
56. Neefjes JJ, Stollorz V, Peters PJ, Geuze HJ, Ploegh HL. The biosynthetic-pathway of MHC class-II but not class-I molecules intersects the endocytic route. Cell 1990;61:171–183.
57. Boniface JJ, Lyons DS, Wettstein DA, Allbritton NL, Davis MM. Evidence for a conformational change in a class II major histocompatibility complex molecule occurring in the same pH range where antigen binding is enhanced. J Exp Med 1996;183:119–126.
58. Kropshofer H, Vogt AB, Moldenhauer G, Hammer J, Blum JS, Hämmerling G. Editing of the HLA-DR-peptide repertoire by HLA-DM. EMBO J 1996;15:6144.
59. Piper RC, Katzmann DJ. Biogenesis and function of multivesicular bodies. Annu Rev Cell Dev Biol 2007;23:519–547.
60. Trombetta ES, Ebersold M, Garrett W, Pypaert M, Mellman I. Activation of lysosomal function during dendritic cell maturation. Science 2003;299:1400–1403.
61. Mellins ED, Stern LJ. HLA-DM and HLA-DO, key regulators of MHC-II processing and presentation. Curr Opin Immunol 2014;26:115–122.
62. Berger AC, Roche PA. MHC class II transport at a glance. J Cell Sci 2009;122:1–4.
63. Wubbolts R, et al. Direct vesicular transport of MHC class II molecules from lysosomal structures to the cell surface. J Cell Biol 1996;135:611–622.
64. Pinet V, Malnati MS, Long EO. 2 Processing pathways for the MHC class II-restricted presentation of exogenous influenza-virus antigen. J Immunol 1994;152:4852–4860.
65. Walseng E, Bakke O, Roche PA. Major histocompatibility complex class II-peptide complexes internalize using a clathrin-and dynamin-independent endocytosis pathway. J Biol Chem 2008;283:14717–14727.
66. Santambrogio L, Sato AK, Fischer FR, Dorf ME, Stern LJ. Abundant empty class II MHC molecules on the surface of immature dendritic cells. Proc Natl Acad Sci USA 1999;96:15050–15055.
67. Allen P, Unanue E. Differential requirements for antigen processing by macrophages for lysozyme-specific T cell hybridomas. J Immunol 1984;132:1077–1079.
68. Germain RN. MHC-dependent antigen-processing and peptide presentation – providing ligands for T-lymphocyte activation. Cell 1994;76:287–299.
69. Jensen PE. Acidification and disulfide reduction can be sufficient to allow intact proteins to bind class-II MHC. J Immunol 1993;150:3347–3356.
70. Marin-Esteban V, Falk K, Rotzschke O. Small-molecular compounds enhance the loading of APC with encephalitogenic MBP protein. J Autoimmun 2003;20:63–69.
71. Pinet V, Vergelli M, Martin R, Bakke O, Long EO. Antigen presentation mediated by recycling of surface HLA-DR molecules. Nature 1995;375:603–606.
72. Vergelli M, et al. T cell response to myelin basic protein in the context of the multiple sclerosis-associated HLA-DR15 haplotype: peptide binding, immunodominance and effector functions of T cells. J Neuroimmunol 1997;77:195–203.
73. Robinson JH, Delvig AA. Diversity in MHC class II antigen presentation. Immunology 2002;105:252–262.
74. Chow A, Toomre D, Garrett W, Mellman I. Dendritic cell maturation triggers retrograde MHC class II transport from lysosomes to the plasma membrane. Nature 2002;418:988–994.
75. Kropshofer H, et al. Tetraspan microdomains distinct from lipid rafts enrich select peptide-MHC class II complexes. Nat Immunol 2002;3:61–68.
76. Anderson HA, Hiltbold EM, Roche PA. Concentration of MHC class II molecules in lipid rafts facilitates antigen presentation. Nat Immunol 2000;1:156–162.
77. Hiltbold EM, Poloso NJ, Roche PA. MHC class II-peptide complexes and APC lipid rafts accumulate at the immunological synapse. J Immunol 2003;170:1329–1338.
78. Pieters J. MHC class II restricted antigen presentation. Curr Opin Immunol 1997;9:89–96.
79. Benaroch P, et al. How MHC class II molecules reach the endocytic pathway. EMBO J 1995;14:37–49.
80. Dugast M, Toussaint H, Dousset C, Benaroch P. AP2 clathrin adaptor complex, but not AP1, controls the access of the major histocompatibility complex (MHC) class II to endosomes. J Biol Chem 2005;280:19656–19664.
81. Chicz RM, Urban RG, Gorga JC, Vignali D, Lane WS, Strominger JL. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 1993;178:27–47.
82. Sercarz EE, Maverakis E. Mhc-guided processing: binding of large antigen fragments. Nat Rev Immunol 2003;3:621–629.
83. Rudensky AY, Preston-Hurlburt P, Al-Ramadi BK, Rothbard J, Janeway CA. Truncation variants of peptides isolated from MHC class II molecules suggest sequence motifs. Nature 1992;359:429–431.
84. Sadegh-Nasseri S, Stern LJ, Wiley DC, Germain RN. MHC class II function preserved by low-affinity peptide interactions preceding stable binding. Nature 1994;370:647–650.
85. Shiina T, Hosomichi K, Inoko H, Kulski JK. The HLA genomic loci map: expression, interaction, diversity and disease. J Hum Genet 2009;54:15–39.
86. Kasson PM, Rabinowitz JD, Schmitt L, Davis MM, McConnell HM. Kinetics of peptide binding to the class II MHC protein I-Ek. Biochemistry (Mosc) 2000;39:1048–1058.
87. Zavala-Ruiz Z, et al. Exploration of the P6/P7 region of the peptide-binding site of the human class II major histocompatability complex protein HLA-DR1. J Biol Chem 2003;278:44904–44912.
88. James EA, Moustakas AK, Bui J, Nouv R, Papadopoulos GK, Kwok WW. The binding of antigenic peptides to HLA-DR is influenced by interactions between pocket 6 and pocket 9. J Immunol 2009;183:3249–3258.
89. McFarland BJ, Beeson C. Binding interactions between peptides and proteins of the class II major histocompatibility complex. Med Res Rev 2002;22:168–203.
90. Sato AK, et al. Determinants of the peptide-induced conformational change in the human class II major histocompatibility complex protein HLA-DR1. J Biol Chem 2000;275:2165–2173.
91. O'Sullivan D, et al. Characterization of the specificity of peptide binding to four DR haplotypes. J Immunol 1990;145:1799–1808.
92. Narayan K, et al. HLA-DM targets the hydrogen bond between the histidine at position β81 and peptide to dissociate HLA-DR–peptide complexes. Nat Immunol 2007;8:92–100.
93. Vogt AB, Kropshofer H, Hammerling GJ. How HLA-DM affects the peptide repertoire bound to HLA-DR molecules. Hum Immunol 1997;54:170–179.
94. Weber DA, Evavold BD, Jensen PE. Enhanced dissociation of HLA-DR-bound peptides in the presence of HLA-DM. Science 1996;274:618–621.
95. Falk K, et al. Ligand exchange of major histocompatibility complex class II proteins is triggered by H-bond donor groups of small molecules. J Biol Chem 2002;277:2709–2715.
96. Denzin LK, Cresswell P. HLA-DM induces CLIP dissociation from MHC class II αβ dimers and facilitates peptide loading. Cell 1995;82:155–165.
97. Reich Z, Boniface JJ, Lyons DS, Borochov N, Wachtel EJ, Davis MM. Ligand-specific oligomerization of T-cell receptor molecules. Nature 1997;387:617–620.
98. Runnels HA, Moore JC, Jensen PE. A structural transition in class II major histocompatibility complex proteins at mildly acidic pH. J Exp Med 1996;183:127–136.
99. Falk K, Rötzschke O. The final cut: how ERAP1 trims MHC ligands to size. Nat Immunol 2002;3:1121–1122.
100. Joshi RV, Zarutskie JA, Stern LJ. A three-step kinetic mechanism for peptide binding to MHC class II proteins. Biochemistry (Mosc) 2000;39:3751–3762.
101. Natarajan SK, Assadi M, Sadegh-Nasseri S. Stable peptide binding to MHC class II molecule is rapid and is determined by a receptive conformation shaped by prior association with low affinity peptides. J Immunol 1999;162:4030–4036.
102. Natarajan SK, Stern LJ, Sadegh-Nasseri S. Sodium dodecyl sulfate stability of HLA-DR1 complexes correlates with burial of hydrophobic residues in pocket 1. J Immunol 1999;162:3463–3470.
103. Qiu Y, Xu XX, Wandingerness A, Dalke DP, Pierce SK. Separation of subcellular compartments containing distinct functional forms of MHC class-II. J Cell Biol 1994;125:595–605.
104. Rabinowitz JD, et al. Formation of a highly peptide-receptive state of class II MHC. Immunity 1998;9:699–709.
105. Rötzschke O, Falk K, Mack J, Lau J, Jung G, Strominger J. Conformational variants of class II MHC/peptide complexes induced by N-and C-terminal extensions of minimal peptide epitopes. Proc Natl Acad Sci USA 1999;96:7445–7450.
106. Viret C, He X, Janeway CA. Altered positive selection due to corecognition of floppy peptide/MHC II conformers supports an integrative model of thymic selection. Proc Natl Acad Sci USA 2003;100:5354–5359.
107. Huang JC, Han M, Minguela A, Pastor S, Qadri A, Ward ES. T cell recognition of distinct peptide: I-Au conformers in murine experimental autoimmune encephalomyelitis. J Immunol 2003;171:2467–2477.
108. Pu Z, Carrero JA, Unanue ER. Distinct recognition by two subsets of T cells of an MHC class II-peptide complex. Proc Natl Acad Sci USA 2002;99:8844–8849.
109. Pu Z, Lovitch SB, Bikoff EK, Unanue ER. T cells distinguish MHC-peptide complexes formed in separate vesicles and edited by H2-DM. Immunity 2004;20:467–476.
110. Ruff JS, Nelson AC, Kubinak JL, Potts WK. MHC signaling during social communication. Adv Exp Med Biol 2012;738:290–313.
111. Zarutskie JA, et al. A conformational change in the human major histocompatibility complex protein HLA-DR1 induced by peptide binding. Biochemistry (Mosc) 1999;38:5878–5887.
112. Marin-Esteban V, Falk K, Rotzschke O. “Chemical analogues” of HLA-DM can induce a peptide-receptive state in HLA-DR molecules. J Biol Chem 2004;279:50684–50690.
113. Painter CA, Cruz A, López GE, Stern LJ, Zavala-Ruiz Z. Model for the peptide-free conformation of class II MHC proteins. PLoS ONE 2008;3:e2403.
114. Stern LJ, Potolicchio I, Santambrogio L. MHC class II compartment subtypes: structure and function. Curr Opin Immunol 2006;18:64–69.
115. Yaneva R, Springer S, Zacharias M. Flexibility of the MHC class II peptide binding cleft in the bound, partially filled, and empty states: a molecular dynamics simulation study. Biopolymers 2009;91:14–27.
116. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007;25:821–852.
117. Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood 2008;112:1557–1569.
118. Behrens G, et al. Helper T cells, dendritic cells and CTL Immunity. Immunol Cell Biol 2004;82:84–90.
119. Vinuesa CG, et al. A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. Nature 2005;435:452–458.
120. Beck A, et al. Peptides as tools and drugs for immunotherapies. J Pept Sci 2007;13:588–602.
121. Eisenbach-Schwartz M, Beserman P, Hirschberg DL. Anti-inflammatory dipeptide and pharmaceutical composition thereof. US6126939-A Patent, 2000.
122. Parmiani G, et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst 2002;94:805–818.
123. Thundimadathil J. Cancer treatment using peptides: current therapies and future prospects. J Amino Acids 2012;2012:1–13.
124. Grotenbreg GM, et al. Empty class II major histocompatibility complex created by peptide photolysis establishes the role of DM in peptide association. J Biol Chem 2007;282:21425–21436.
125. Ferrante A. HLA-DM: arbiter conformationis. Immunology 2013;138:85–92.
126. Stratikos E, Wiley DC, Stern LJ. Enhanced catalytic action of HLA-DM on the exchange of peptides lacking backbone hydrogen bonds between their N-terminal region and the MHC class II alpha-chain. J Immunol 2004;172:1109–1117.
127. Narayan K, Su KW, Chou CL, Khoruzhenko S, Sadegh-Nasseri S. HLA-DM mediates peptide exchange by interacting transiently and repeatedly with HLA-DR1. Mol Immunol 2009;46:3157–3162.
128. Davies MN, Lamikanra A, Sansom CE, Flower DR, Moss DS, Travers PJ. Identification of the HLA-DM/HLA-DR interface. Mol Immunol 2008;45:1063–1070.
129. Kelly AP, Monaco JJ, Cho S, Trowsdale J. A new human HLA class II-related locus, DM. Nature 1991;353:571–573.
130. Pashine A, et al. Interaction of HLA-DR with an acidic face of HLA-DM disrupts sequence-dependent interactions with peptides. Immunity 2003;19:183–192.
131. Arndt SO, et al. Functional HLA-DM on the surface of B cells and immature dendritic cells. EMBO J 2000;19:1241–1251.
132. Pathak SS, Lich JD, Blum JS. Cutting edge: editing of recycling class II: peptide complexes by HLA-DM. J Immunol 2001;167:632–635.
133. Call MJ, et al. In vivo enhancement of peptide display by MHC class II molecules with small molecule catalysts of peptide exchange. J Immunol 2009;182:6342–6352.
134. Lanzavecchia A, Reid PA, Watts C. Irreversible association of peptides with class II MHC molecules in living cells. Nature 1992;357:249–252.
135. Dickhaut K, et al. Enhancement of tumour-specific immune responses in vivo by ‘MHC loading-enhancer’ (MLE). PLoS ONE 2009;4:e6811.
136. Mlecnik B, Bindea G, Pagès F, Galon J. Tumor immunosurveillance in human cancers. Cancer Metastasis Rev 2011;30:5–12.
137. De Wall SL, et al. Noble metals strip peptides from class II MHC proteins. Nat Chem Biol 2006;2:197–201.
138. Nicholson MJ, et al. Small molecules that enhance the catalytic efficiency of HLA-DM. J Immunol 2006;176:4208–4220.
139. Ferrante A, Gorski J. Cutting edge: HLA-DM-mediated peptide exchange functions normally on MHC class II-peptide complexes that have been weakened by elimination of a conserved hydrogen bond. J Immunol 2010;184:1153–1158.
140. Mosyak L, Zaller DM, Wiley DC. The structure of HLA-DM, the peptide exchange catalyst that loads antigen onto class II MHC molecules during antigen presentation. Immunity 1998;9:377–383.
141. Painter CA, Stern LJ. Structural insights into HLA-DM mediated MHC II peptide exchange. Curr Topics Biochem Res 2011;13:39–55.
142. Pos W, et al. Crystal structure of the HLA-DM–HLA-DR1 complex defines mechanisms for rapid peptide selection. Cell 2012;151:1557–1568.
143. Kolesanova EF, Sanzhakov MA, Kharybin ON. Development of the schedule for multiple parallel “difficult” Peptide synthesis on pins. Int J Pept 2013;2013:197317.
144. Schulze MS, Anders AK, Sethi DK, Call MJ. Disruption of hydrogen bonds between major histocompatibility complex class II and the peptide N-terminus is not sufficient to form a human leukocyte antigen-DM receptive state of major histocompatibility complex class II. PLoS ONE 2013;8:e69228.
145. Chou C-L, Sadegh-Nasseri S. HLA-DM recognizes the flexible conformation of major histocompatibility complex class II. J Exp Med 2000;192:1697–1706.
146. Denzin LK, Hammond C, Cresswell P. HLA-DM interactions with intermediates in HLA-DR maturation and a role for HLA-DM in stabilizing empty HLA-DR molecules. J Exp Med 1996;184:2153–2166.
147. Doebele RC, Busch R, Scott HM, Pashine A, Mellins ED. Determination of the HLA-DM interaction site on HLA-DR molecules. Immunity 2000;13:517–527.
148. Kropshofer H, Arndt SO, Moldenhauer G, Hämmerling GJ, Vogt AB. HLA-DM acts as a molecular chaperone and rescues empty HLA-DR molecules at lysosomal pH. Immunity 1997;6:293–302.
149. Ong B, et al. Critical role for the Val/Gly86 HLA-DR beta dimorphism in autoantigen presentation to human T cells. Proc Natl Acad Sci USA 1991;88:7343–7347.
150. Zaheer Ul H, Khan W. Molecular and structural determinants of adamantyl susceptibility to HLA-DRs allelic variants: an in silico approach to understand the mechanism of MLEs. J Comput Aided Mol Des 2011;25:81–101.
151. + T cells in the antitumor immune response. J Exp Med 1998;188:2357–2368.
152. Toes RE, et al. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. J Immunol 1998;160:4449–4456.
153. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005;22:329–341.
154. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004;22:531–562.
155. Borghouts C, Kunz C, Groner B. Current strategies for the development of peptide-based anti-cancer therapeutics. J Pept Sci 2005;11:713–726.
156. Thayer A. Making peptides at large scale. Chem Eng News 2011;89:81–85.
157. Craik DJ, Fairlie DP, Liras S, Price D. The future of peptide-based drugs. Chem Biol Drug Des 2013;81:136–147.
158. Li W, Joshi MD, Singhania S, Ramsey KH, Murthy AK. Peptide vaccine: progress and challenges. Vaccines 2014;2:515–536.
159. Aguilar J, Rodriguez E. Vaccine adjuvants revisited. Vaccine 2007;25:3752–3762.
160. Liu J-Y, et al. Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine. Cancer Immunol Immunother 2007;56:1597–1604.
161. Solares AM, et al. Safety and immunogenicity of a human papillomavirus peptide vaccine (CIGB-228) in women with high-grade cervical intraepithelial neoplasia: first-in-human. Proof-of-concept trial. ISRN Obstet Gynecol 2011;2011:292951.
162. Tarradas J, et al. Interferon-gamma induction correlates with protection by DNA vaccine expressing E2 glycoprotein against classical swine fever virus infection in domestic pigs. Vet Microbiol 2010;142:51–58.
163. Staneková Z, Vareckova E. Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development. Virol J 2010;7:351.
164. Oscherwitz J, Yu F, Cease KB. A synthetic peptide vaccine directed against the 2β2–2β3 loop of domain 2 of protective antigen protects rabbits from inhalation anthrax. J Immunol 2010;185:3661–3668.
165. Epstein JE, et al. Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: an update. J Infect Dis 2007;196:145–154.
166. Volpina OM, Gelfanov VM, Yarov AV, Surovoy AY, Chepurkin AV, Ivanov VT. New virus-specific T-helper epitopes of foot-and-mouth disease viral VP 1 protein. FEBS Lett 1993;333:175–178.
167. Bernhardt S, et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study. Br J Cancer 2006;95:1474–1482.
168. Kyte JA, Gaudernack G, Dueland S, Trachsel S, Julsrud L, Aamdal S. Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients. Clin Cancer Res 2011;17:4568–4580.
169. Brunsvig PF, et al. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother 2006;55:1553–1564.
170. + T-cell responses in patients with advanced HCC. J Immunother 2010;33:211–218.
171. Kyte JA. Cancer vaccination with telomerase peptide GV1001. Expert Opin Investig Drugs 2009;18:687–694.
172. Akhtar F, Rizvi MMA, Kar SK. Oral delivery of curcumin bound to chitosan nanoparticles cured Plasmodium yoelii infected mice. Biotechnol Adv 2012;30:310–320.
173. Garetto S, Sizzano F, Brusa D, Tizzani A, Malavasi F, Matera L. Binding of prostate-specific membrane antigen to dendritic cells: a critical step in vaccine preparation. Cytotherapy 2009;11:1090–1100.
174. Grunnet M, Sorensen J. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer 2012;76:138–143.
175. Kaufman DR, Li F, Cruz AN, Self SG, Barouch DH. Focus and breadth of cellular immune responses elicited by a heterologous insert prime-boost vaccine regimen in rhesus monkeys. Vaccine 2012;30:506–509.
176. Ahrens CH, Russell RLQ, Funk CJ, Evans JT, Harwood SH, Rohrmann GF. The sequence of the Orgyia pseudotsugata multinucleocapsid nuclear polyhedrosis virus genome. Virology 1997;229:381–399.
177. Markowicz S, et al. Adjuvant vaccination with melanoma antigen-pulsed dendritic cells in stage III melanoma patients. Med Oncol 2012;29:2966–2977.
178. Muderspach L, et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 2000;6:3406–3416.
179. Nava-Parada P, Emens LA. GV-1001, an injectable telomerase peptide vaccine for the treatment of solid cancers. Curr Opin Mol Ther 2007;9:490–497.
180. Weber J, et al. A novel method for the simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3′ Gag (p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: a useful tool in the multi-target era of antiretroviral therapy. Antimicrob Agents Chemother 2011;55:3729–3742. AAC. 00396-00311.
181. Yamada A, Sasada T, Noguchi M, Itoh K. Next-generation peptide vaccines for advanced cancer. Cancer Sci 2013;104:15–21.
182. Yamamoto K, et al. MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer. Anticancer Res 2005;25:3575–3579.
183. Yang H, Hu B, Xiao L, Wang P. Dendritic cell-directed lentivector vaccine induces antigen-specific immune responses against murine melanoma. Cancer Gene Ther 2011;18:370–380.
184. Afridi S, et al. A cyclic peptide accelerates the loading of peptide antigens in major histocompatibility complex class II molecules. Biochem Biophys Res Commun 2015;456:774–779.
185. Michałowicz J, Duda W. Phenols – Sources and Toxicity. Polish J. of Environ. Stud. 2007;16:347–362.